280 related articles for article (PubMed ID: 30116751)
21. T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway.
Rodriguez-Barbosa JI; Fernandez-Renedo C; Moral AMB; Bühler L; Del Rio ML
Cell Mol Immunol; 2017 Jun; 14(6):497-510. PubMed ID: 26924526
[TBL] [Abstract][Full Text] [Related]
22. Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.
Bai Y; Shi Y; Li Y; Cai B; Zou Y; Wang L
Transpl Immunol; 2013 Jan; 28(1):38-47. PubMed ID: 23165214
[TBL] [Abstract][Full Text] [Related]
23. Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.
Kuncewicz K; Battin C; Sieradzan A; Karczyńska A; Orlikowska M; Wardowska A; Pikuła M; Steinberger P; Rodziewicz-Motowidło S; Spodzieja M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238640
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of herpes virus entry mediator expression in hepatitis B virus-related hepatocellular carcinoma.
Yi Y; Ni XC; Liu G; Yin YR; Huang JL; Gan W; Zhou PY; Guan RY; Zhou C; Sun BY; Qiu SJ
Oncol Lett; 2020 Oct; 20(4):19. PubMed ID: 32774492
[TBL] [Abstract][Full Text] [Related]
25. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
Derré L; Rivals JP; Jandus C; Pastor S; Rimoldi D; Romero P; Michielin O; Olive D; Speiser DE
J Clin Invest; 2010 Jan; 120(1):157-67. PubMed ID: 20038811
[TBL] [Abstract][Full Text] [Related]
26. Unconventional ligand activation of herpesvirus entry mediator signals cell survival.
Cheung TC; Steinberg MW; Oborne LM; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6244-9. PubMed ID: 19332782
[TBL] [Abstract][Full Text] [Related]
27. Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors.
Sun WZ; Lin HW; Chen WY; Chien CL; Lai YL; Chen J; Chen YL; Cheng WF
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463789
[TBL] [Abstract][Full Text] [Related]
28. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
29. Cutting Edge: the BTLA-HVEM regulatory pathway interferes with protective immunity to intestinal Helminth infection.
Breloer M; Hartmann W; Blankenhaus B; Eschbach ML; Pfeffer K; Jacobs T
J Immunol; 2015 Feb; 194(4):1413-6. PubMed ID: 25595777
[TBL] [Abstract][Full Text] [Related]
30. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
Murphy TL; Murphy KM
Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
[TBL] [Abstract][Full Text] [Related]
31. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.
Sakoda Y; Park JJ; Zhao Y; Kuramasu A; Geng D; Liu Y; Davila E; Tamada K
Blood; 2011 Feb; 117(8):2506-14. PubMed ID: 21220749
[TBL] [Abstract][Full Text] [Related]
32. The intrahepatic expression and distribution of BTLA and its ligand HVEM in patients with HBV-related acute-on-chronic liver failure.
Xu H; Cao D; Guo G; Ruan Z; Wu Y; Chen Y
Diagn Pathol; 2012 Oct; 7():142. PubMed ID: 23067542
[TBL] [Abstract][Full Text] [Related]
33. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
[TBL] [Abstract][Full Text] [Related]
34. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
35. CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells.
Thibult ML; Rivals JP; Mamessier E; Gertner-Dardenne J; Pastor S; Speiser DE; Derré L; Olive D
J Mol Med (Berl); 2013 Feb; 91(2):195-205. PubMed ID: 22903545
[TBL] [Abstract][Full Text] [Related]
36. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.
Wang S; Ljubimov AV; Jin L; Pfeffer K; Kronenberg M; Ghiasi H
J Virol; 2018 Dec; 92(24):. PubMed ID: 30282707
[TBL] [Abstract][Full Text] [Related]
37. B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis.
Vendel AC; Jaroszewski L; Linnik MD; Godzik A
Clin Pharmacol Ther; 2024 Apr; ():. PubMed ID: 38676311
[TBL] [Abstract][Full Text] [Related]
38. Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells.
Wang XF; Chen YJ; Wang Q; Ge Y; Dai Q; Yang KF; Fang-Xie ; Zhou YH; Hu YM; Mao YX; Zhang XG
Tissue Antigens; 2007 Feb; 69(2):145-53. PubMed ID: 17257317
[TBL] [Abstract][Full Text] [Related]
39. [Expression and Significance of BTLA and Its Ligand HVEM in Patients with Chronic Myelomonocytic Leukemia].
Li C; Geng SX; Li MM; Su F; Chen XM; Deng CX; Huang X; Lai PL; Weng JY; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):56-62. PubMed ID: 32027253
[TBL] [Abstract][Full Text] [Related]
40. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
Spodzieja M; Kuncewicz K; Sieradzan A; Karczyńska A; Iwaszkiewicz J; Cesson V; Węgrzyn K; Zhukov I; Maszota-Zieleniak M; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
